{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:22:55Z","timestamp":1792264975828,"version":"4.4.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,27]]},"DOI":"10.7759\/cureus.28484","type":"journal-article","created":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T03:45:31Z","timestamp":1661658331000},"source":"Crossref","is-referenced-by-count":34,"title":["Huntington's Disease: A Clinical Review"],"prefix":"10.7759","author":[{"given":"Rajeshwar","family":"Andhale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti","family":"Shrivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/09647040600820050","article-title":"Vinken and Bruyn's handbook of clinical neurology","volume":"17","author":"Koehler PJ","year":"2008","unstructured":"Koehler PJ, Jennekens FG. Vinken and Bruyn's handbook of clinical neurology. J Hist Neurosci. 2008, 17:46-55. 10.1080\/09647040600820050","journal-title":"J Hist Neurosci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90585-e","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes","volume":"72","author":"Macdonald M","year":"1993","unstructured":"Macdonald M. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell. 1993, 72:971-83. 10.1016\/0092-8674(93)90585-e","journal-title":"Cell"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30280-6","article-title":"Therapies targeting DNA and RNA in Huntington's disease","volume":"16","author":"Wild EJ","year":"2017","unstructured":"Wild EJ, Tabrizi SJ. Therapies targeting DNA and RNA in Huntington's disease. Lancet Neurol. 2017, 16:837-47. 10.1016\/S1474-4422(17)30280-6","journal-title":"Lancet Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/ng0494-409","article-title":"Somatic and gonadal mosaicism of the Huntington\u2019s disease gene CAG repeats in the brain and sperm","volume":"6","author":"Telenius H","year":"1994","unstructured":"Telenius H, Kremer B, Goldberg YP, et al.. Somatic and gonadal mosaicism of the Huntington\u2019s disease gene CAG repeats in the brain and sperm. Nature Gen. 1994, 6:409-14. 10.1038\/ng0494-409","journal-title":"Nature Gen"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington disease","volume":"1","author":"Bates GP","year":"2015","unstructured":"Bates GP, Dorsey R, Gusella JF, et al.. Huntington disease. Nat Rev Dis Primers. 2015, 1:15005. 10.1038\/nrdp.2015.5","journal-title":"Nat Rev Dis Primers"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington\u2019s disease: from molecular pathogenesis to clinical treatment","volume":"10","author":"Ross CA","year":"2011","unstructured":"Ross CA, Tabrizi SJ. Huntington\u2019s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011, 10:83-98. 10.1016\/S1474-4422(10)70245-3","journal-title":"Lancet Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.conb.2015.01.020","article-title":"Corticostriatal synaptic adaptations in Huntington's disease","volume":"33","author":"Plotkin JL","year":"2015","unstructured":"Plotkin JL, Surmeier DJ. Corticostriatal synaptic adaptations in Huntington's disease. Curr Opin Neurobiol. 2015, 33:53-62. 10.1016\/j.conb.2015.01.020","journal-title":"Curr Opin Neurobiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008287","article-title":"Dopamine D2 receptor stimulation potentiates PolyQ-Huntingtin-induced mouse striatal neuron dysfunctions via Rho\/ROCK-II activation","volume":"4","author":"Deyts C","year":"2009","unstructured":"Deyts C, Galan-Rodriguez B, Martin E, et al.. Dopamine D2 receptor stimulation potentiates PolyQ-Huntingtin-induced mouse striatal neuron dysfunctions via Rho\/ROCK-II activation. PLoS One. 2009, 4:e8287. 10.1371\/journal.pone.0008287","journal-title":"PLoS One"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2015.10.038","article-title":"RAN translation in Huntington disease","volume":"88","author":"Ba\u00f1ez-Coronel M","year":"2015","unstructured":"Ba\u00f1ez-Coronel M, Ayhan F, Tarabochia AD, et al.. RAN translation in Huntington disease. Neuron. 2015, 88:667-77. 10.1016\/j.neuron.2015.10.038","journal-title":"Neuron"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/00005072-199805000-00001","article-title":"Huntington disease","volume":"57","author":"Vonsattel JP","year":"1998","unstructured":"Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol. 1998, 57:369-84. 10.1097\/00005072-199805000-00001","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/00005072-198511000-00003","article-title":"Neuropathological classification of Huntington's disease","volume":"44","author":"Vonsattel JP","year":"1985","unstructured":"Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol. 1985, 44:559-77. 10.1097\/00005072-198511000-00003","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.2007.19.4.441","article-title":"Psychopathology in verified Huntington\u2019s disease gene carriers","volume":"19","author":"van Duijn E","year":"2007","unstructured":"van Duijn E, Kingma EM, van der Mast RC. Psychopathology in verified Huntington\u2019s disease gene carriers. J Neuropsychiatry Clin Neurosci. 2007, 19:441-8. 10.1176\/jnp.2007.19.4.441","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000052992.58107.67","article-title":"Predictors of nursing home placement in Huntington disease","volume":"60","author":"Wheelock VL","year":"2003","unstructured":"Wheelock VL, Tempkin T, Marder K, et al.. Predictors of nursing home placement in Huntington disease. Neurology. 2003, 60:998-1001. 10.1212\/01.wnl.0000052992.58107.67","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejhg.5201284","article-title":"Huntington\u2019s disease, third edition: Oxford monographs on medical genetics","volume":"12","author":"Kohan ZG","year":"2004","unstructured":"Kohan ZG. Huntington\u2019s disease, third edition: Oxford monographs on medical genetics. Eur J Hum Genet. 2004, 12:1084. 10.1038\/sj.ejhg.5201284","journal-title":"Eur J Hum Genet"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000334276.09729.0e","article-title":"Weight loss in Huntington disease increases with higher CAG repeat number","volume":"71","author":"Aziz NA","year":"2008","unstructured":"Aziz NA, van der Burg JM, Landwehrmeyer GB, Brundin P, Stijnen T, Roos RA. Weight loss in Huntington disease increases with higher CAG repeat number. Neurology. 2008, 71:1506-13. 10.1212\/01.wnl.0000334276.09729.0e","journal-title":"Neurology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(91)90443-w","article-title":"The hypothalamic lateral tuberal nucleus and the characteristics of neuronal loss in Huntington\u2019s disease","volume":"132","author":"Kremer HP","year":"1991","unstructured":"Kremer HP, Roos RA, Dingjan GM, et al.. The hypothalamic lateral tuberal nucleus and the characteristics of neuronal loss in Huntington\u2019s disease. Neurosci Lett. 1991, 132:101-4. 10.1016\/0304-3940(91)90443-w","journal-title":"Neurosci Lett"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1515\/revneuro.2007.18.3-4.223","article-title":"Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington's disease: clinical consequences and therapeutic implications","volume":"18","author":"Aziz NA","year":"2007","unstructured":"Aziz NA, Swaab DF, Pijl H, Roos RA. Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington's disease: clinical consequences and therapeutic implications. Rev Neurosci. 2007, 18:223-51. 10.1515\/revneuro.2007.18.3-4.223","journal-title":"Rev Neurosci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.65.4.482","article-title":"Rapid eye movement sleep disturbances in Huntington disease","volume":"65","author":"Arnulf I","year":"2008","unstructured":"Arnulf I, Nielsen J, Lohmann E, et al.. Rapid eye movement sleep disturbances in Huntington disease. Arch Neurol. 2008, 65:482-8. 10.1001\/archneur.65.4.482","journal-title":"Arch Neurol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2217\/nmt.13.18","article-title":"Managing juvenile Huntington's disease","volume":"3","author":"Quarrell OW","year":"2013","unstructured":"Quarrell OW, Nance MA, Nopoulos P, Paulsen JS, Smith JA, Squitieri F. Managing juvenile Huntington's disease. Neurodegener Dis Manag. 2013, 3:267-76. 10.2217\/nmt.13.18","journal-title":"Neurodegener Dis Manag"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.29.1.1","article-title":"Huntington disease: clinical care and evaluation","volume":"29","author":"Shoulson I","year":"1979","unstructured":"Shoulson I, Fahn S. Huntington disease: clinical care and evaluation. Neurology. 1979, 29:1. 10.1212\/wnl.29.1.1","journal-title":"Neurology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870110204","article-title":"Unified Huntington's Disease Rating Scale: reliability and consistency","volume":"11","author":"Huntington Study Group","year":"1996","unstructured":"Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord. 1996, 11:136-42. 10.1002\/mds.870110204","journal-title":"Mov Disord"},{"key":"ref22","unstructured":"Huntington Study Group. (2021). Accessed. July 31, 2022: http:\/\/www.huntington-study-group.org."},{"key":"ref23","unstructured":"European Huntington\u2019s Disease Network. Accessed. July 31, 2022: http:\/\/www.ehdn.org\/."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.24","article-title":"Huntington disease: natural history, biomarkers and prospects for therapeutics","volume":"10","author":"Ross CA","year":"2014","unstructured":"Ross CA, Aylward EH, Wild EJ, et al.. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol. 2014, 10:204-16. 10.1038\/nrneurol.2014.24","journal-title":"Nat Rev Neurol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21915","article-title":"Huntington's disease phenocopies are clinically and genetically heterogeneous","volume":"23","author":"Wild EJ","year":"2008","unstructured":"Wild EJ, Mudanohwo EE, Sweeney MG, et al.. Huntington's disease phenocopies are clinically and genetically heterogeneous. Mov Disord. 2008, 23:716-20. 10.1002\/mds.21915","journal-title":"Mov Disord"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000061","article-title":"C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies","volume":"82","author":"Hensman Moss DJ","year":"2014","unstructured":"Hensman Moss DJ, Poulter M, Beck J, et al.. C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies. Neurology. 2014, 82:292-9. 10.1212\/WNL.0000000000000061","journal-title":"Neurology"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0b013e3282f12074","article-title":"Huntington's disease phenocopy syndromes","volume":"20","author":"Wild EJ","year":"2007","unstructured":"Wild EJ, Tabrizi SJ. Huntington's disease phenocopy syndromes. Curr Opin Neurol. 2007, 20:681-7. 10.1097\/WCO.0b013e3282f12074","journal-title":"Curr Opin Neurol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/306234a0","article-title":"A polymorphic DNA marker genetically linked to Huntington's disease","volume":"306","author":"Gusella JF","year":"1983","unstructured":"Gusella JF, Wexler NS, Conneally PM, et al.. A polymorphic DNA marker genetically linked to Huntington's disease. Nature. 1983, 306:234-8. 10.1038\/306234a0","journal-title":"Nature"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.31.7.555","article-title":"International Huntington Association and the World Federation of Neurology Research Group on Huntington's Chorea. Guidelines for the molecular genetics predictive test in Huntington's disease","volume":"31","year":"1994","unstructured":"International Huntington Association and the World Federation of Neurology Research Group on Huntington's Chorea. Guidelines for the molecular genetics predictive test in Huntington's disease. J Med Genet. 1994, 31.555-9. 10.1136\/jmg.31.7.555","journal-title":"J Med Genet"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1096-8628(19991215)88:6<662::aid-ajmg16>3.0.co;2-a","article-title":"Predictive testing of 25 percent at-risk individuals for Huntington disease (1987-1997)","volume":"88","author":"Maat-Kievit A","year":"1999","unstructured":"Maat-Kievit A, Vegter-Van Der Vlis M, Zoeteweij M, et al.. Predictive testing of 25 percent at-risk individuals for Huntington disease (1987-1997). Am J Med Genet. 1999, 88:662-8. 10.1002\/(sici)1096-8628(19991215)88:6&lt;662::aid-ajmg16&gt;3.0.co;2-a","journal-title":"Am J Med Genet"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejhg.5201774","article-title":"The complexity of reproductive decision-making in asymptomatic carriers of the Huntington mutation","volume":"15","author":"Decruyenaere M","year":"2007","unstructured":"Decruyenaere M, Evers-Kiebooms G, Boogaerts A, et al.. The complexity of reproductive decision-making in asymptomatic carriers of the Huntington mutation. Eur J Hum Genet. 2007, 15:453-62. 10.1038\/sj.ejhg.5201774","journal-title":"Eur J Hum Genet"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial","volume":"66","author":"Huntington Study Group","year":"2006","unstructured":"Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006, 66:366-72. 10.1212\/01.wnl.0000198586.85250.13","journal-title":"Neurology"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0670-4","article-title":"Current pharmacological approaches to reduce chorea in Huntington's disease","volume":"77","author":"Coppen EM","year":"2017","unstructured":"Coppen EM, Roos RA. Current pharmacological approaches to reduce chorea in Huntington's disease. Drugs. 2017, 77:29-46. 10.1007\/s40265-016-0670-4","journal-title":"Drugs"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.8655","article-title":"Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial","volume":"316","author":"Frank S","year":"2016","unstructured":"Frank S, Testa CM, Stamler D, et al.. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA. 2016, 316:40-50. 10.1001\/jama.2016.8655","journal-title":"JAMA"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12483","article-title":"Tetrabenazine versus deutetrabenazine for Huntington's disease: twins or distant cousins?","volume":"4","author":"Rodrigues FB","year":"2017","unstructured":"Rodrigues FB, Duarte GS, Costa J, Ferreira JJ, Wild EJ. Tetrabenazine versus deutetrabenazine for Huntington's disease: twins or distant cousins?. Mov Disord Clin Pract. 2017, 4:582-5. 10.1002\/mdc3.12483","journal-title":"Mov Disord Clin Pract"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(16)30144-4","article-title":"Changes in mental state and behaviour in Huntington\u2019s disease","volume":"3","author":"Eddy CM","year":"2016","unstructured":"Eddy CM, Parkinson EG, Rickards HE. Changes in mental state and behaviour in Huntington\u2019s disease. Lancet Psychiat. 2016, 3:1079-86. 10.1016\/S2215-0366(16)30144-4","journal-title":"Lancet Psychiat"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/109169-huntingtons-disease-a-clinical-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:48:51Z","timestamp":1707508131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/109169-huntingtons-disease-a-clinical-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,27]]},"references-count":36,"URL":"https:\/\/doi.org\/10.7759\/cureus.28484","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,27]]}}}